🔍

HALEOSLABS - Haleos Labs Limited

📊 NSE: HALEOSLABS 🏢 Pharmaceuticals 📅 Last Updated: 11/13/2025 15:25

📢 Recent Corporate Announcements

Haleos Labs Reopens Special Window for Physical Share Transfer Re-lodgment

🟡 NEUTRAL ⭐ 3/10

REGULATORY 📅 28 Feb 2026, 01:27 PM

Haleos Labs Limited has announced a special one-year window for the re-lodgment of physical share transfer requests, effective from February 5, 2026, to February 4, 2027. This facility is specifically designed for transfer deeds that were originally submitted before the April 1, 2019, deadline but were rejected or returned due to documentation deficiencies. The move follows a SEBI circular dated January 30, 2026, aimed at resolving pending physical share issues. Additionally, the company has reminded shareholders to claim dividends older than seven years to prevent them from being transferred to the Investor Education & Protection Fund (IEPF).

Special window for physical share transfer re-lodgment open from February 5, 2026, to February 4, 2027.
Applicable only to transfer deeds lodged prior to the April 1, 2019, deadline that were previously rejected or unprocessed.
Action taken in compliance with SEBI circular no. HO/38/13/11(2)2026-MIRSD-POD/1I3750/2026.
Shareholders reminded to claim dividends older than 7 years to avoid transfer of shares and funds to the IEPF.

💡 Shareholders holding physical certificates with previously rejected transfer requests should utilize this one-year window to regularize their holdings. For most equity investors, this is a routine regulatory update with no impact on the company's financial performance.

Haleos Labs Q3 FY26 Consolidated Net Profit Rises 37% YoY to ₹6.65 Cr; Revenue Up 12%

🟢 POSITIVE ⭐ 8/10

EARNINGS 📅 11 Feb 2026, 07:06 PM

Haleos Labs Limited (formerly SMS Lifesciences) reported a strong consolidated performance for Q3 FY26, with revenue growing 12% YoY to ₹94.78 crore. Consolidated net profit surged 37% YoY to ₹6.65 crore, driven by improved operational efficiencies and lower finance costs. The board also approved a corporate guarantee for its subsidiary, Mahi Drugs, to facilitate External Commercial Borrowing (ECB), indicating potential expansion plans. While standalone revenue saw a slight dip, the consolidated numbers reflect robust growth from subsidiary operations.

Consolidated Revenue from Operations increased 12% YoY to ₹94.78 crore from ₹84.60 crore.
Consolidated Net Profit grew 37% YoY to ₹6.65 crore compared to ₹4.85 crore in Q3 FY25.
Consolidated EPS rose to ₹21.89 for the quarter, up from ₹18.08 in the corresponding previous year quarter.
Finance costs on a consolidated basis decreased to ₹1.54 crore from ₹2.14 crore YoY.
Board approved a corporate guarantee for subsidiary Mahi Drugs for External Commercial Borrowing, subject to shareholder approval.

💡 Investors should view the strong consolidated profit growth and debt reduction in finance costs as positive indicators. Monitor the upcoming postal ballot regarding the corporate guarantee for Mahi Drugs as it signals future capital expenditure or expansion.

Haleos Labs Partners with HRV Global for Orphan Drug and Niche API Manufacturing

🟢 POSITIVE ⭐ 7/10

EXPANSION 📅 21 Jan 2026, 01:34 PM

Haleos Labs Limited has entered into a strategic development collaboration with HRV Global Life Sciences to accelerate the manufacturing of orphan drugs and niche therapeutic APIs. The partnership combines Haleos' USFDA-GMP aligned manufacturing expertise with HRV Global's international regulatory and market access capabilities. This initiative targets high-value, underserved therapeutic segments in major regulated markets including the US and EU. The collaboration is designed to strengthen the company's global footprint across Latin America, MENA, and APAC regions through coordinated development pathways.

Strategic collaboration with HRV Global Life Sciences for orphan drug and niche therapeutic APIs
Leverages Haleos' USFDA-GMP manufacturing systems for high-value complex molecules
Targets expansion into regulated and semi-regulated markets including US, EU, and Latin America
Focuses on underserved therapeutic segments to improve product mix and margins
HRV Global to lead regulatory execution and global market access initiatives

💡 Investors should view this as a positive move toward high-margin niche segments; monitor for specific product pipeline updates and regulatory filings in the US and EU markets.

Haleos Labs Reports Nil Requests in Special Window for Physical Share Transfer Re-lodgment

🟡 NEUTRAL ⭐ 2/10

REGULATORY 📅 13 Jan 2026, 04:49 PM

Haleos Labs Limited has submitted its action taken report regarding the SEBI-mandated special window for re-lodging physical share transfer requests. For the period from December 1, 2025, to January 6, 2026, the company reported that zero requests were received from shareholders. This filing marks the conclusion of the special window period which originally opened on July 7, 2025. As no requests were received, there is no impact on the company's shareholding structure or administrative workload.

Special window for re-lodgment of physical share transfers was open from July 7, 2025, to January 6, 2026.
Zero (0) requests were received or processed during the final reporting period of Dec 1, 2025, to Jan 6, 2026.
The filing is in compliance with SEBI circular SEBI/HO/MIRSD/MIRSD-PoD/P/CIR/2025/97.
Aarthi Consultants Private Limited acted as the Registrar and Share Transfer Agent (RTA) for this process.

💡 No action is required for investors as this is a routine regulatory compliance update with no operational or financial impact.

Haleos Labs Submits Q3 FY26 Compliance Certificate Under SEBI Regulation 74(5)

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 07 Jan 2026, 05:22 PM

Haleos Labs Limited has submitted its quarterly compliance certificate for the period ending December 31, 2025, in accordance with SEBI (Depositories and Participants) Regulations. The company's Registrar and Share Transfer Agent, Aarthi Consultants Private Limited, confirmed that all share certificates received for dematerialization were processed within the mandated 15-day timeframe. This filing confirms that physical certificates were mutilated and cancelled, and the depository's name was substituted in the records as the registered owner. This is a standard administrative procedure ensuring the integrity of the company's shareholding data.

Compliance certificate issued for the quarter ended December 31, 2025.
RTA confirms processing of dematerialization requests within the 15-day regulatory window.
Verification provided by Aarthi Consultants Private Limited regarding share certificate cancellation.
The filing confirms the substitution of the depository as the registered owner for dematerialized shares.

💡 This is a routine regulatory filing with no impact on the company's financial performance or stock valuation. No action is required from investors.

Haleos Labs Announces Trading Window Closure from January 1, 2026

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 20 Dec 2025, 02:05 PM

Haleos Labs Limited, formerly known as SMS Lifesciences India Limited, has announced the closure of its trading window effective January 1, 2026. This action is in compliance with SEBI Prohibition of Insider Trading Regulations ahead of the financial results for the quarter and nine months ending December 31, 2025. The window will remain closed for all designated persons and their immediate relatives until 48 hours after the results are publicly disclosed. The specific date for the board meeting to approve these results will be communicated at a later date.

Trading window closure begins on January 1, 2026
Closure is for the financial results of the quarter and nine months ending December 31, 2025
Restriction applies to designated persons, connected persons, and their immediate relatives
Window will reopen 48 hours after the declaration of the unaudited financial results

💡 This is a routine regulatory announcement and does not impact the company's fundamentals. Investors should monitor for the upcoming board meeting date to review the Q3 FY2026 financial performance.

Haleos Labs Reports Nil Requests in Special Window for Physical Share Transfers in November 2025

🟡 NEUTRAL ⭐ 2/10

REGULATORY 📅 08 Dec 2025, 06:02 PM

Haleos Labs Limited has submitted its monthly action taken report regarding the SEBI-mandated special window for re-lodgment of physical share transfer requests. For the month of November 2025, the company received zero requests from shareholders. This special window was opened on July 7, 2025, and is scheduled to remain active until January 6, 2026. The filing confirms that no processing or approvals were required during this period, maintaining a status quo on physical share transfers.

Special window for re-lodgment of physical share transfers is open from July 7, 2025, to January 6, 2026.
Zero (NIL) requests were received, processed, or approved during the month of November 2025.
The report is in compliance with SEBI circular dated July 2, 2025, regarding historical share transfer issues.
Aarthi Consultants Private Limited continues to act as the Registrar and Share Transfer Agent (RTA) for these requests.

💡 No action is required for investors holding shares in demat form. Shareholders still holding physical certificates should ensure any pending transfer issues are addressed before the January 6, 2026 deadline.

View All HALEOSLABS Announcements on Live Market Tracking →

💰 Financial Performance

Revenue Growth by Segment

Total revenue from operations grew 11.12% to INR 333.37 Cr in FY25. Segment-wise: Sale of APIs grew 4.67% to INR 204.99 Cr; Intermediates grew 16.33% to INR 98.89 Cr; and Sale of Services grew 197.57% to INR 17.14 Cr. Other sales (Others) declined by 7.77% to INR 12.35 Cr.

Geographic Revenue Split

The company focuses on regulated markets including the US and Brazil, alongside emerging opportunities in frontier economies. Specific percentage splits per region are not disclosed in the available documents.

Profitability Margins

Net Profit Margin improved significantly by 47.19%, rising from 4.36% in FY24 to 6.41% in FY25. Operating Profit Margin increased by 13.29% to 14.45% in FY25 compared to 12.76% in FY24. Return on Net Worth increased by 49.04% to 11.45% due to improved operational profitability.

EBITDA Margin

EBITDA grew 25.89% YoY to INR 48.18 Cr in FY25 from INR 38.27 Cr in FY24. The EBITDA margin stands at 14.45%, reflecting enhanced operational efficiency and a shift toward higher-margin services and intermediates.

Capital Expenditure

The company has undertaken a capital expenditure of INR 145 Cr since its demerger to augment the next leg of growth and enhance manufacturing capabilities.

Credit Rating & Borrowing

The company maintains moderate working capital utilization at approximately 67% for the 12 months ending September 2023. Debt-Equity ratio improved by 25.53%, falling from 0.51 to 0.40 in FY25 due to liability reduction and increased net worth.

⚙️ Operational Drivers

Raw Materials

Specific chemical names are not listed, but raw materials are noted to be subject to price fluctuations and lead-time risks associated with imports. Raw material costs (Cost of Goods Sold) represented 67.39% of revenue in FY25 (INR 224.67 Cr).

Import Sources

The company sources raw materials internationally, with a strategic focus on mitigating risks associated with imports, particularly from China as part of the 'China Plus One' strategy.

Capacity Expansion

Current combined installed capacity is 800 KL. The company is focused on capacity enhancement to meet growing global demand, though specific future KL targets are not quantified.

Raw Material Costs

Cost of goods sold was INR 224.67 Cr in FY25, a 5.63% increase YoY, which is lower than the 11.12% revenue growth, indicating better procurement or pricing power.

Manufacturing Efficiency

Inventory Turnover Ratio improved by 27.46% to 4.93 in FY25. Inventory days decreased by 21.55% from 94.32 days to 74.00 days, reflecting significantly improved manufacturing and sales velocity.

📈 Strategic Growth

Expected Growth Rate

11.12%

Growth Strategy

The company aims to increase its product portfolio to 50+ products by FY2028. Strategy includes backward integration for cost leadership, strategic alliances with global business associates, and focusing on complex, niche APIs in regulated markets like the US and Brazil.

Products & Services

Active Pharmaceutical Ingredients (APIs) such as Ranitidine Hcl, Intermediates, and Contract Manufacturing services.

Brand Portfolio

Haleos Labs (formerly SMS Lifesciences India Limited); Mahi Drugs (Subsidiary).

New Products/Services

Expansion to 50+ products by FY2028 from the current portfolio, focusing on niche and complex API segments.

Market Expansion

Targeting regulated markets (USA, Brazil) and emerging frontier economies to diversify the customer base and reduce geographic risk.

Market Share & Ranking

The company is one of the single-largest manufacturers of Ranitidine Hcl globally, providing a significant competitive advantage in that specific therapeutic segment.

Strategic Alliances

Actively pursuing alliances and partnerships with global business associates to enrich the product portfolio and access new customer segments.

🌍 External Factors

Industry Trends

The industry is shifting toward 'China Plus One' sourcing and niche/complex product segments. Growth is driven by increased health insurance penetration and rising chronic disease prevalence.

Competitive Landscape

Operates in a highly fragmented and regulated bulk drug industry with intense competition from both domestic and international API manufacturers.

Competitive Moat

Moat is built on USFDA-compliant manufacturing facilities (Unit 1 and Mahi Drugs) and global leadership in specific products like Ranitidine Hcl. Sustainability is supported by long-standing customer relationships and economies of scale.

Macro Economic Sensitivity

Highly sensitive to government policies and regulatory reforms which can simplify processes and enhance growth prospects in the pharmaceutical sector.

Consumer Behavior

Increasing demand for generic penetration in regulated markets and growing demand from semi-regulated pharma markets.

Geopolitical Risks

Political and economic instability in export markets and supply chain dependencies on imports are identified as key threats.

⚖️ Regulatory & Governance

Industry Regulations

Subject to Drugs and Cosmetics Act (1940), DPCO (2013), NDPS Act (1985), and USFDA inspections. Unit 1 had one procedural observation in May 2025, while Mahi Drugs had no observations in Jan 2025.

Environmental Compliance

The company enhanced effluent treatment capacities at Unit 1 and Unit 4 to comply with Water, Air, and Environment Protection Acts.

Taxation Policy Impact

Tax expense for FY25 was INR 8.67 Cr, an increase of 43.54% YoY, following the 57.20% increase in Profit Before Tax.

Legal Contingencies

The company created a provision of INR 5.06 Cr for doubtful trade receivables in FY25 to address credit risks. No specific pending court case values were disclosed.

⚠️ Risk Analysis

Key Uncertainties

Regulatory changes in the pharmaceutical sector and USFDA audit outcomes represent the highest impact risks (potential impact not quantified but noted as 'critical').